Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805 November 16, 2022
Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with BMS November 4, 2022
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models November 4, 2022
Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK November 4, 2022
Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer November 2, 2022
HOOKIPA Announces Strategic Collaboration And License Agreement With Roche To Develop Novel Arenaviral Immunotherapy For KRAS-Mutated Cancers October 26, 2022
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination October 26, 2022
Kite And Refuge Biotechnologies Announce Exclusive License Agreement For Investigational Gene Expression Platform For Blood Cancers October 26, 2022
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab October 26, 2022
Gilead And MacroGenics Announce Oncology Collaboration To Develop Bispecific Antibodies October 26, 2022
Mirati Therapeutics & Aadi Bioscience Partner to Evaluate Adagrasib + Nab-sirolimus in Advanced NSCLC and Other Solid Tumors patients with a KRAS[G12C] Mutation October 19, 2022
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Balstilimab in a Ph 2 Study in Primary Glioblastoma Patients October 19, 2022
Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs October 19, 2022
Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors October 19, 2022
Allogene Therapeutics Launches CAR T Together™ Initiative Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products October 19, 2022
Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Ph 1b STELLAR-002 Trial October 12, 2022
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System October 12, 2022
Kite Receives U.S. FDA Approval Of Viral Vector Manufacturing Facility In Southern California To Produce Commercial Product October 12, 2022
TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory NSCLC October 5, 2022
Seagen & LAVA Therapeutics to Advance LAVA-1223, a Gamma Delta BiTE for EGFR-Expressing Solid Tumors October 5, 2022
Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor September 28, 2022
